CORONA Remedies Limited has informed the Exchange regarding Board meeting held on January 02, 2026.
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CORONA Remedies, a recently listed pharma company (IPO on Dec 15, 2025), reported its first set of quarterly results since listing. Q2 FY26 revenue stood at ₹361.13 Cr, up 15.1% YoY, while H1 FY26 revenue was ₹707.67 Cr, up 17.0% YoY. Profit after tax for Q2 was ₹52.32 Cr (+21.8% YoY) and H1 was ₹98.52 Cr (+35.1% YoY). EBITDA margin came in at 21.7% for Q2 and 20.9% for H1. The company also reported strong return ratios with RoE of 31.1% and RoCE of 49.7%. Operating cash flow for H1 was ₹113.44 Cr with OCF/EBITDA conversion of 76.5%. The auditor (Deloitte Haskins & Sells LLP) issued an unmodified limited review report.
This is a strong debut post-listing earnings print with double-digit revenue growth, robust 35% PAT growth in H1, healthy margins, and best-in-class return ratios. Positive read for shareholders as profitability scaled faster than revenue, indicating operating leverage. Management scheduled an earnings call on January 5, 2026 to provide further detail.